| scientific integrity review | Designation for reports by the united states office of research integrity, identifying questionable research published in articles or books. Notification of the questionable data is carried in the nih guide for grants and contracts. (12 Dec 1998) |
|---|---|
| drug utilization review | Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for medicaid programs beginning in 1993. (12 Dec 1998) |
| insurance claim review | Review of claims by insurance companies to determine liability and amount of payment for various services. The review may also include determination of eligibility of the claimant or beneficiary or of the provider of the benefit; determination that the benefit is covered or not payable under another policy; or determination that the service was necessary and of reasonable cost and quality. (12 Dec 1998) |
| utilization review | An organised procedure carried out through committees to review admissions, duration of stay, professional services furnished, and to evaluate the medical necessity of those services and promote their most efficient use. (12 Dec 1998) |
| retrospective studies | Studies used to test aetiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. (12 Dec 1998) |
| pharmalogical studies | <pharmacology> Studies to assess the potential harmful or other effects of drugs (16 Dec 1997) |
| clinical studies | <pharmacology> Human studies that are designed to measure the safety, efficacy, and appropriate dosage of a new drug or biological. Clinical studies routinely involve the use of a placebo group that is given an inactive substance that looks like the test product. (14 Nov 1997) |
| cohort studies | Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesised to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. (12 Dec 1998) |
| combination studies | <pharmacology> Studies in which a new drug is evaluated in combination with existing drugs. (09 Jan 1998) |
| multicenter studies | Controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children. (12 Dec 1998) |
| multivariate studies | The use of statistical techniques for the simultaneous investigations of the influence of several variables. (05 Mar 2000) |
| preclinical studies | <pharmacology> Studies in which a drug is tested on animals and in other non-human test systems. Safety information from such studies are used to support an investigational new drug application. (14 Nov 1997) |
| sampling studies | Studies in which a number of subjects are selected from all subjects in a defined population. Conclusions based on sample results may be attributed only to the population sampled. (12 Dec 1998) |
| prospective studies | Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. (12 Dec 1998) |
| his bundle studies | <cardiology> This test studies the electrical activity of the bundle of HIS. The bundle of HIS is a group of electrical fibres in the heart that are responsible for transmitting the electrical impulses which generate a normal cardiac contraction. This test may be performed in cases of cardiac arrhythmias, to locate a specific area responsible for a conduction defect and to determine the need for cardiac pacemaker placement. The test involves the passage of a an electrode tipped catheter into the heart. This catheter is usually threaded through a neck, arm or chest vein. Measurements of the HIS bundle can then be performed while standard ECG leads are placed on the arms and legs. This test carries a small risk of bleeding, arrhythmias, embolism, heart attack and stroke. It is performed by a specially trained cardiologist. (27 Sep 1997) |